证券代码：300109 证券简称：新开源 公告编号：2026-023 博爱新开源医疗科技集团股份有限公司 关于回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、本次回购注销的股份合计 2,669,400 股，占回购注销前公司总股本的 0.55%，本次回购注销完成后,公司总股本由 486,050,005 股减少至 483,380,605 股。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次回购 股份注销事宜已于 2026 年 3 月 27 日办理完成。 博爱新开源医疗科技集团股份有限公司（以下简称"公司"）于 2026 年 1 月 7 日召开第五届董事会第二十一次会议、1 月 27 日召开 2026 年第二次临时股东 大会逐项审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同 意公司使用自有资金以集中竞价交易方式回购股份用于注销并减少注册资本。回 购资金总额为不低于人民币 4,000 万元（含本数）且不超过人民币 5,000 万元（含 本数），具体以回购期满时实际回购股份使用的资金总额为 ...

证券代码：300109 证券简称：新开源 公告编号：2026-022 博爱新开源医疗科技集团股份有限公司 关于董事会延期换届的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博爱新开源医疗科技集团股份有限公司（以下简称"公司"）第五届董事会 任期将于 2026 年 3 月 23 日届满。 鉴于新一届董事会董事候选人的提名工作尚未完成，为保证公司董事会工作 的连续性及稳定性，公司董事会换届选举工作将延期进行，同时公司第五届董事 会各专门委员会和高级管理人员的任期亦相应顺延。 在董事会换届选举工作完成之前，公司第五届董事会、董事会各专门委员会 成员及高级管理人员将继续依照法律法规和《公司章程》的相关规定，履行相应 的职责和义务。 公司董事会延期换届不影响公司的正常运营。公司将积极推进董事会的换届 选举工作，并按照有关规定及时履行信息披露义务。 特此公告 博爱新开源医疗科技集团股份有限公司 董事会 2026 年 3 月 20 日 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300109 证券简称：新开源 公告编号：2026-021 博爱新开源医疗科技集团股份有限公司 关于回购股份实施结果暨股份变动的公告 博爱新开源医疗科技集团股份有限公司（以下简称"公司"）于 2026 年 1 月 7 日召开第五届董事会第二十一次会议、1 月 27 日召开 2026 年第二次临时股东 会逐项审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意 公司使用自有资金以集中竞价交易方式回购股份用于注销并减少注册资本。回购 资金总额为不低于人民币 4,000 万元（含本数）且不超过人民币 5,000 万元（含 本数），具体以回购期满时实际回购股份使用的资金总额为准；回购价格上限为 25.77 元/股；回购股份的实施期限为自公司临时股东会审议通过本次回购方案之 日 起 6 个 月 内 。 具 体 内 容 详 见 公 司 于 2026 年 1 月 27 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2026-015）。 截至 2026 年 ...

Group 1: Company Overview and Leadership - The meeting was held on March 17, 2026, in Shanghai, with key personnel including Chairman Zhang Junzheng and Vice General Manager Wang Shigang [2] - The presentation covered the development history of the company and an overview of its two main business segments [2] Group 2: PVP Product Insights - Current PVP product prices are low, but future price recovery is expected as the industry undergoes capacity clearing and consolidation [3] - The company plans to increase PVP production capacity by 15,000 tons, aiming for a total capacity of over 20,000 tons per year [3] - The current capacity utilization rate for PVP is high, aligning well with market demand [3] - The company is focusing on optimizing its product structure to increase the proportion of high-end products, which is expected to improve gross margins [3] Group 3: Raw Material and Market Conditions - The core raw material for the company's products, BDO, has remained stable with slight fluctuations since 2026, without significant price increases [3] - Rising oil prices have not yet impacted the pricing of the company's related products [3] Group 4: Investment in Biopharmaceuticals - The company has invested in five pharmaceutical-related entities, with key products under development including EAL® for liver cancer and CAR-T therapies [4][5] - Strategic cooperation is underway with Huada Biotech for the construction of a CAR-T drug production facility with an annual capacity of 8,000 to 10,000 doses [5] Group 5: Profit Distribution and Shareholder Returns - From 2022 to 2024, the company achieved a cumulative net profit of approximately 20.24 billion CNY, with cash dividends totaling about 11.34 billion CNY [5] - The cash dividend amount over the past three years accounted for approximately 89.15% of the net profit during the same period [5] - The company is committed to maintaining a high dividend payout ratio while balancing long-term development and operational funding needs [5]

| 股东名称 | 减持方式 | 减持期间 | 减持均价 | 减持股数 | 变动比例（%） | | --- | --- | --- | --- | --- | --- | | | | | （元/股） | （股） | | | 于江涛 | 集中竞价 | 2025.12.25 | 17.45 | 60,000 | 0.012 | | | | 2025.12.31 | 16.86 | 70,000 | 0.014 | 证券代码：300109 证券简称：新开源 公告编号：2026-020 博爱新开源医疗科技集团股份有限公司 关于部分董事、高级管理人员股份减持计划期限届满暨实施 情况的公告 董事于江涛先生、高级管理人员邢小亮先生保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 博爱新开源医疗科技集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 11 月 25 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于部分董事、 高级管理人员股份减持计划的预披露公告》（公告编号：2025-040），公司 ...

Group 1: Company Overview and Business Segments - The company operates in two main business segments: Fine Chemicals (approximately 90% revenue share) and Precision Medicine (approximately 10% revenue share) [4] - The Fine Chemicals segment is the dominant business, with plans to increase the proportion of high-end products and optimize product structure [4] - The Precision Medicine segment is currently experiencing slight losses, but improvements are expected to lead to profitability between 2026 and 2027 [4] Group 2: PVP Product Insights - The current production capacity for NVP monomer is approximately 35,000 tons, making it the largest globally, while PVP production capacity is limited to 20,000 tons per year due to downstream polymerization constraints [4] - The company plans to add 15,000 tons of new PVP production capacity to enhance downstream capabilities [4] - PVP products account for about 50% of the company's exports, with significant markets in Europe, India, and South Asia [4] Group 3: Industry Applications and Future Projections - In the renewable energy sector, PVP is used as a dispersant for carbon nanotubes in solid-state batteries, with expected sales of approximately 4,000 tons in 2025 and a projected 20% growth in 2026 [5] - The company has already shipped about 200 tons of PVP products to the photovoltaic industry in 2025, with anticipated growth in 2026 [5] Group 4: Euriz Product and Strategic Transition - Euriz, a product line of vinyl ether/maleic anhydride copolymer, has a high gross margin of approximately 60-70% and exports about 90% of its output [7] - The company aims to transition from a capacity-driven model to one focused on technology and service leadership, with a comprehensive quality and service optimization plan set for 2025-2027 [7] Group 5: Management and Market Strategy - Some executives have reduced their holdings primarily due to personal financing needs related to stock incentives from 2021, with market conditions influencing future decisions on further reductions [8] - The company's market value is currently affected by its share structure and business development, with plans to optimize the share structure and increase the proportion of high-end products to enhance market capitalization [9] Group 6: Investment in Innovative Drug Development - The company has strategically invested in five cell and gene therapy companies, focusing on innovative drug development, with significant investments including HKD 40 million in Yongtai Bio and CNY 150 million in Huada Bio [10] - Future product launches from these investments are expected within three to five years, with ongoing collaborations for commercialization and market expansion [11]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博爱新开源医疗科技集团股份有限公司（以下简称"公司"）于 2026 年 1 月 7 日召开第五届董事会第二十一次会议、1 月 27 日召开 2026 年第二次临时股东 大会逐项审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同 意公司使用自有资金以集中竞价交易方式回购股份用于注销并减少注册资本。回 购资金总额为不低于人民币 4,000 万元（含本数）且不超过人民币 5,000 万元（含 本数），具体以回购期满时实际回购股份使用的资金总额为准；回购价格上限为 25.77 元/股；回购股份的实施期限为自公司临时股东大会审议通过本次回购方案 之日起 6 个月内。具体内容详见公司于 2026 年 1 月 27 日在巨潮资讯网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2026-015）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司在回购股份期间应当在每个月的前三个交 易日内披露截至上月末的回购进展情况。现将截至 2026 ...

Group 1 - The research team from the Chinese Academy of Sciences has developed a "histidine scanning method" that can quickly locate key sites on T cell receptors (TCR) responsible for recognizing cancer cells and initiating clearance programs [1] - The modified TCR molecules act as highly sensitive enhanced "security scanners," significantly improving T cells' ability to eliminate cancer cells [1] - This method does not rely on the three-dimensional structural information of TCR molecules, allowing for simultaneous modification of multiple key sites to enhance the ability of TCRs to capture cancer cells [1] Group 2 - The modified T cells exhibit higher activation levels and stronger killing power, with the ability to accurately distinguish between cancerous and healthy cells, thus avoiding collateral damage [1] - The research has shown significant efficacy in animal models, providing a new approach for developing the next generation of efficient and precise cancer immunotherapies [1] - Related A-share concept stocks include Hanyu Pharmaceutical and New Source [2]

Core Viewpoint - The company reported that as of February 10, the number of shareholders is approximately 19,100 [2] Group 1 - The company engaged with investors through an interactive platform [2] - The date of the shareholder count is noted as February 10 [2] - The total number of shareholders is approximately 19,100 [2]

Core Insights - The report by Frost & Sullivan indicates a significant increase in the daily usage of enterprise-level large models in China, with a rise to 37 trillion tokens in the second half of 2025, marking a 263% increase from 10.2 trillion tokens in the first half [1][3]. Group 1: Market Dynamics - The primary drivers for enterprises using large models shifted from enhancing product performance and customer experience in the first half of 2025 to improving operational efficiency and R&D effectiveness in the second half [3]. - The market for enterprise-level large models is rapidly consolidating around leading vendors, with the top three models (Qwen, Doubao, and DeepSeek) accounting for over 70% of daily token consumption in the second half of 2025, compared to less than half in the first half [3][4]. Group 2: Vendor Performance - Alibaba Cloud's Qwen model saw its market share nearly double to 32.1% in the second half of 2025, with a growth rate of 14.4% [3][4]. - The report highlights that enterprises are increasingly favoring fewer vendors to reduce long-term operational costs related to interface maintenance and version management, creating higher migration barriers for leading vendors [4]. Group 3: Open Source Trends - There is a notable increase in enterprises' willingness to adopt open-source models, with the proportion of closed-source users planning to add open-source options doubling from 22.6% in the first half to 48.5% in the second half of 2025 [4]. - Chinese companies accounted for 90.2% of the global new open-source large models introduced in the second half of 2025, significantly outpacing international competitors [4]. Group 4: Competitive Landscape - The competition among domestic open-source models has expanded beyond single-point performance to include size, deployment flexibility, and cost control [5]. - Since its launch in 2023, Qwen has released over 400 models, achieving over 1 billion downloads and extending its language capabilities to 201 languages, establishing itself as the leading open-source model globally [5].